NBIO.US Nascent Biotech Inc

Healthcare Biotechnology USA Stocks
0.0004 USD
Close of Nov 13, 2026
0.0001 0.0077
Market cap
USD 68.9K
P/E
-
P/B
482.01x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2024.

Is NBIO.US undervalued?

Graham number

The Graham number of Nascent Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nascent Biotech Inc fundamental analysis

No fundamental analysis for Nascent Biotech Inc yet.

Nascent Biotech Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nascent Biotech Inc

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.

Full company profile